An Open-label, Multicenter, Phase II Clinical Study to Evaluate HRS-7058 in Patients With Pancreatic Cancer

Prior treatment

• Subjects who had received general anesthesia
• Subjects with poor blood pressure control after medication
• Participated in clinical trials of other drugs (received experimental drugs)

Other illness

• Presence of untreated or active central nervous system (CNS) metastases. Participants with a history of leptomeningeal metastasis or current leptomeningeal metastasis, brainstem metastasis, spinal cord metastasis, and/or spinal cord compression.
• Subjects with a history of myocardial infarction or unstable angina pectoris
• Subjects with atrioventricular block or cardiac insufficiency
• Subjects with a history of ischemic stroke or transient ischemic attack
• Subjects with a history of mental illness and a history of cognitive impairment epilepsy
• Subject with a history of substance abuse and drug abuse
• Allergic to a drug ingredient or component
• The inestigators determined that other conditions were inappropriate for participation in this clinical trial

Lab values

• Abnormal values in the laboratory

Other

• Subjects with abnormal clotting function
• Subjects with a history or possibility of a difficult airway
• Adrenoceptor agonists or antagonists were used before randomization
• Thyroid dysfunction
• Pregnant or nursing women
• No birth control during the specified period of time

• Informed consent was obtained from all participants before participating in the study.
• Age from 18 to 75 years old (including both ends), regardless of gender;
• Patients with locally advanced unresectable, recurrent unresectable or metastatic pancreatic cancer, and adenocarcinoma confirmed by cytology or histological pathology;
• Participants had received at least one previous systemic therapy
• At least one measurable lesion according to RECIST v1.1;
• ECOG PS score 0 or 1;
• The expected survival time was more than 3 months.
• They were able to swallow medications and were able to adhere to trial and follow-up procedures.
• Adequate bone marrow and organ function within 7 days before the first dose (no use of blood components and/or cell growth factors within 14 days before starting study treatment;
• Women of childbearing potential had to agree to abstain from sexual intercourse (heterosexual intercourse) or to use a highly effective method of contraception from the time they provided informed consent until 30 days after the last dose of the trial drug. A blood test for human chorionic gonadotropin (HCG) had to be negative within 7 days before starting study treatment and she had to be nonlactating (if a serum pregnancy test was positive, pregnancy was ruled out and enrollment was confirmed after discussion with the sponsor). Men whose partner was a woman of childbearing potential had to agree to abstain from sex or to use a highly effective method of contraception from the time they provided written informed consent until 30 days after the last dose of the trial drug. Male patients also had to agree not to donate sperm during the same period